Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
- PMID: 28814432
- PMCID: PMC5705850
- DOI: 10.1136/annrheumdis-2017-211384
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
Abstract
Background: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of maternal CZP.
Methods: CRADLE (NCT02154425) was a pharmacokinetic study of lactating mothers receiving CZP. After ≥3 CZP doses, breast milk samples were collected across one dosing period (14 days for 200 mg every 2 weeks [Q2W]; 28 days for 400 mg every 4 weeks [Q4W]). Optimal analytical methods were developed to determine CZP and polyethylene glycol (PEG) levels in breast milk. ADID and relative infant dose (RID) were estimated. Safety events in mothers and infants were assessed.
Results: 19 CZP-treated mothers were screened; 17 entered the sampling period: 16 on 200 mg Q2W, 1 on 400 mg Q4W. 77/137 (56%) breast milk samples had no measurable CZP. For 4/17 mothers, all samples were below the lower limit of quantification (LLOQ). Estimated ADID was 0-0.0104 mg/kg/day; median RID: 0.15%. PEG was undetectable in 134/137 samples (results could not be determined in three samples). Infants of CZP-exposed mothers had a safety profile consistent with that of unexposed similar-age infants.
Conclusion: When quantifiable, CZP concentrations were <3× LLOQ (<1% plasma concentration observed with therapeutic dose), indicating no/minimal CZP transfer from plasma to breast milk. RID was 0.15% of maternal dose; <10% is considered unlikely to be of clinical concern. No PEG transfer was observed. CZP absorption by infants via breast milk is unlikely due to its low oral bioavailability and Fc--free molecular structure. These findings are reassuring and support continuation of CZP treatment during breast feeding.
Trial registration number: NCT02154425; Results.
Keywords: Anti-tnf; Autoimmune Diseases; Rheumatoid Arthritis; Spondyloarthritis.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: MEBC has received research support from Janssen and Pfizer and is a consultant for UCB Pharma; FF has received research grants from UCB Pharma and is a consultant for and/or has received speakers’ fees from Mepha, Roche and UCB Pharma; CH has received research support from AbbVie and UCB Pharma and is a consultant for Janssen; JT has received research grants from UCB Pharma and is a consultant for Genentech/Roche and UCB Pharma; RJEMD has received unrestricted research grants from UCB Pharma; AvT has received research grants and/or clinical trial support from AbbVie, Celgene, Janssen Cilag, MSD, Novartis, Pfizer and UCB Pharma, has received speakers’ bureau from Janssen Cilag, MSD and Pfizer and is a consultant for and/or has served on advisory boards for AbbVie, Janssen Cilag, Novartis and Pfizer; LS, JS, MT, NT and MW are employees of UCB Pharma; TWH is a consultant for UCB Pharma.
Figures
Similar articles
-
Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.Gastroenterology. 2018 Sep;155(3):696-704. doi: 10.1053/j.gastro.2018.05.040. Epub 2018 May 30. Gastroenterology. 2018. PMID: 29857090
-
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.Ann Rheum Dis. 2018 Feb;77(2):228-233. doi: 10.1136/annrheumdis-2017-212196. Epub 2017 Oct 13. Ann Rheum Dis. 2018. PMID: 29030361 Free PMC article. Clinical Trial.
-
Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.Joint Bone Spine. 2016 May;83(3):341-3. doi: 10.1016/j.jbspin.2015.07.004. Epub 2015 Nov 23. Joint Bone Spine. 2016. PMID: 26617214
-
Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.BioDrugs. 2014 Apr;28 Suppl 1:S15-23. doi: 10.1007/s40259-013-0064-z. BioDrugs. 2014. PMID: 24687235 Review.
-
Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.Health Technol Assess. 2010 Oct;14(Suppl. 2):1-10. doi: 10.3310/hta14suppl2/01. Health Technol Assess. 2010. PMID: 21047485 Review.
Cited by
-
[Treatment of psoriasis vulgaris : Therapy strategies for optimal patient-centered care].Dermatologie (Heidelb). 2024 May;75(5):417-427. doi: 10.1007/s00105-024-05310-1. Epub 2024 Mar 7. Dermatologie (Heidelb). 2024. PMID: 38451270 Review. German.
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi: 10.1007/s40262-023-01341-4. Epub 2024 Jan 27. Clin Pharmacokinet. 2024. PMID: 38280146 Review.
-
The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clin Rheumatol. 2024 Mar;43(3):879-894. doi: 10.1007/s10067-024-06867-x. Epub 2024 Jan 13. Clin Rheumatol. 2024. PMID: 38217738 Free PMC article. Review.
-
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.Pediatric Health Med Ther. 2023 Nov 14;14:435-451. doi: 10.2147/PHMT.S389108. eCollection 2023. Pediatric Health Med Ther. 2023. PMID: 38024562 Free PMC article. Review.
-
Ornidazole Transfer into Colostrum and Assessment of Exposure Risk for Breastfeeding Infant: A Population Pharmacokinetic Analysis.Pharmaceutics. 2023 Oct 24;15(11):2524. doi: 10.3390/pharmaceutics15112524. Pharmaceutics. 2023. PMID: 38004504 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources